Where is ABclonal located?

ABclonal is headquartered in Taipei, Taiwan.

Is ABclonal a funded company?

ABclonal is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does ABclonal rank among its competitors?

ABclonal ranks 229th amongst 305 active competitors, of which 38 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Abselion, which secured $8.41M in Oct, 2024.

Who are the top competitors of ABclonal?

ABclonal's top competitors include Illumina, Quanterix and BioLife Solutions. Among them, Abselion secured the most recent funding round in October, 2024.

ABclonal - 2026 Company Profile & Competitors

Company Details

AB Clonal is a provider of diversified services and solutions. The product portfolio includes NGS Lib Prep Kits, Antibodies, proteins, ELISA kits, and transfection reagents. It also offers services like peptide synthesize, peptide library, custom antibodies and protein services like E.coli Expression, insect cell expression, mammalian cell expression.

Website: abclonalbio.com
Social
Email ID: *****@abclonal.com
Phone Number: +886 **********

Key Metrics

Founded Year

2019

Location

Taipei, Taiwan

Stage

Unfunded

Ranked

229^th among 305 active competitors

Similar Companies

Illumina & 352 more

View ABclonal's full profile

ABclonal has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ABclonal include Illumina, Quanterix and BioLife Solutions. Here is the list of Top 10 competitors of ABclonal, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Illumina 1993, San Diego (United States), Public	Developer of technologies for analysis of genetic variation and function	$28M	Chevron Technology Ventures, Dow Chemical Company ... & 32 others	71/100
2nd	Quanterix 2007, Cambridge (United States), Public	Developer of assay kits for ultra-sensitive biomarker detection	$99.5M	T. Rowe Price, Hercules Capital & 15 others	71/100
3rd	BioLife Solutions 1987, Bothell (United States), Public	Developer of cell and gene therapies with the integrity of a single cell	-	-	67/100
4th	Biocare Medical 1997, Concord (United States), Acquired	Manufacturer of primary antibodies and instruments for immunohistochemistry applications	$85M	Excellere Partners, GHO Capital Partners & 3 others	65/100
5th	MGI 2016, Shenzhen (China), Series B	Provider of gene sequencing instruments, reagents, equipment, and related products	$1B	Guotai Junan Securities, CPE & 13 others	64/100
6th	Siemens Healthineers 1847, Forchheim (Germany), Public	Developer of AI-based medical diagnostic products for the healthcare sector	-	Skyviews Life Science, Europa & 1 others	62/100
7th	Mapi Pharma 2008, Ness Ziona (Israel), Series B	Clinical stage pharmaceutical company developing extended release versions of generic drugs.	$60M	aMoon, Shavit Capital & 3 others	62/100
8th	Bio-Techne 1981, Minneapolis (United States), Public	Developer of biotech reagents, instruments and clinical diagnostic products	-	HHS	59/100
9th	Abselion 2018, Cambridge (United Kingdom), Series A	Provider of a benchtop instrument for protien research	$12.6M	University of Cambridge, M Ventures & 13 others	59/100
10th	Bio Rad 1952, Hercules (United States), Public	Portfolio of products and services for life science research and clinical diagnostic markets	-	Bellevue Healthcare Trust, Europa & 3 others	58/100
229th	ABclonal 2019, Taipei (Taiwan), Unfunded	Provider of diversified services and solutions	-	-	24/100